Cargando…
Mesenchymal stromal cell labeling by new uncoated superparamagnetic maghemite nanoparticles in comparison with commercial Resovist – an initial in vitro study
OBJECTIVE: Cell therapies have emerged as a promising approach in medicine. The basis of each therapy is the injection of 1–100×10(6) cells with regenerative potential into some part of the body. Mesenchymal stromal cells (MSCs) are the most used cell type in the cell therapy nowadays, but no gold s...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4245086/ https://www.ncbi.nlm.nih.gov/pubmed/25484583 http://dx.doi.org/10.2147/IJN.S66986 |
_version_ | 1782346307057221632 |
---|---|
author | Skopalik, Josef Polakova, Katerina Havrdova, Marketa Justan, Ivan Magro, Massimiliano Milde, David Knopfova, Lucia Smarda, Jan Polakova, Helena Gabrielova, Eva Vianello, Fabio Michalek, Jaroslav Zboril, Radek |
author_facet | Skopalik, Josef Polakova, Katerina Havrdova, Marketa Justan, Ivan Magro, Massimiliano Milde, David Knopfova, Lucia Smarda, Jan Polakova, Helena Gabrielova, Eva Vianello, Fabio Michalek, Jaroslav Zboril, Radek |
author_sort | Skopalik, Josef |
collection | PubMed |
description | OBJECTIVE: Cell therapies have emerged as a promising approach in medicine. The basis of each therapy is the injection of 1–100×10(6) cells with regenerative potential into some part of the body. Mesenchymal stromal cells (MSCs) are the most used cell type in the cell therapy nowadays, but no gold standard for the labeling of the MSCs for magnetic resonance imaging (MRI) is available yet. This work evaluates our newly synthesized uncoated superparamagnetic maghemite nanoparticles (surface-active maghemite nanoparticles – SAMNs) as an MRI contrast intracellular probe usable in a clinical 1.5 T MRI system. METHODS: MSCs from rat and human donors were isolated, and then incubated at different concentrations (10–200 μg/mL) of SAMN maghemite nanoparticles for 48 hours. Viability, proliferation, and nanoparticle uptake efficiency were tested (using fluorescence microscopy, xCELLigence analysis, atomic absorption spectroscopy, and advanced microscopy techniques). Migration capacity, cluster of differentiation markers, effect of nanoparticles on long-term viability, contrast properties in MRI, and cocultivation of labeled cells with myocytes were also studied. RESULTS: SAMNs do not affect MSC viability if the concentration does not exceed 100 μg ferumoxide/mL, and this concentration does not alter their cell phenotype and long-term proliferation profile. After 48 hours of incubation, MSCs labeled with SAMNs show more than double the amount of iron per cell compared to Resovist-labeled cells, which correlates well with the better contrast properties of the SAMN cell sample in T2-weighted MRI. SAMN-labeled MSCs display strong adherence and excellent elasticity in a beating myocyte culture for a minimum of 7 days. CONCLUSION: Detailed in vitro tests and phantom tests on ex vivo tissue show that the new SAMNs are efficient MRI contrast agent probes with exclusive intracellular uptake and high biological safety. |
format | Online Article Text |
id | pubmed-4245086 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-42450862014-12-05 Mesenchymal stromal cell labeling by new uncoated superparamagnetic maghemite nanoparticles in comparison with commercial Resovist – an initial in vitro study Skopalik, Josef Polakova, Katerina Havrdova, Marketa Justan, Ivan Magro, Massimiliano Milde, David Knopfova, Lucia Smarda, Jan Polakova, Helena Gabrielova, Eva Vianello, Fabio Michalek, Jaroslav Zboril, Radek Int J Nanomedicine Original Research OBJECTIVE: Cell therapies have emerged as a promising approach in medicine. The basis of each therapy is the injection of 1–100×10(6) cells with regenerative potential into some part of the body. Mesenchymal stromal cells (MSCs) are the most used cell type in the cell therapy nowadays, but no gold standard for the labeling of the MSCs for magnetic resonance imaging (MRI) is available yet. This work evaluates our newly synthesized uncoated superparamagnetic maghemite nanoparticles (surface-active maghemite nanoparticles – SAMNs) as an MRI contrast intracellular probe usable in a clinical 1.5 T MRI system. METHODS: MSCs from rat and human donors were isolated, and then incubated at different concentrations (10–200 μg/mL) of SAMN maghemite nanoparticles for 48 hours. Viability, proliferation, and nanoparticle uptake efficiency were tested (using fluorescence microscopy, xCELLigence analysis, atomic absorption spectroscopy, and advanced microscopy techniques). Migration capacity, cluster of differentiation markers, effect of nanoparticles on long-term viability, contrast properties in MRI, and cocultivation of labeled cells with myocytes were also studied. RESULTS: SAMNs do not affect MSC viability if the concentration does not exceed 100 μg ferumoxide/mL, and this concentration does not alter their cell phenotype and long-term proliferation profile. After 48 hours of incubation, MSCs labeled with SAMNs show more than double the amount of iron per cell compared to Resovist-labeled cells, which correlates well with the better contrast properties of the SAMN cell sample in T2-weighted MRI. SAMN-labeled MSCs display strong adherence and excellent elasticity in a beating myocyte culture for a minimum of 7 days. CONCLUSION: Detailed in vitro tests and phantom tests on ex vivo tissue show that the new SAMNs are efficient MRI contrast agent probes with exclusive intracellular uptake and high biological safety. Dove Medical Press 2014-11-20 /pmc/articles/PMC4245086/ /pubmed/25484583 http://dx.doi.org/10.2147/IJN.S66986 Text en © 2014 Skopalik et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Skopalik, Josef Polakova, Katerina Havrdova, Marketa Justan, Ivan Magro, Massimiliano Milde, David Knopfova, Lucia Smarda, Jan Polakova, Helena Gabrielova, Eva Vianello, Fabio Michalek, Jaroslav Zboril, Radek Mesenchymal stromal cell labeling by new uncoated superparamagnetic maghemite nanoparticles in comparison with commercial Resovist – an initial in vitro study |
title | Mesenchymal stromal cell labeling by new uncoated superparamagnetic maghemite nanoparticles in comparison with commercial Resovist – an initial in vitro study |
title_full | Mesenchymal stromal cell labeling by new uncoated superparamagnetic maghemite nanoparticles in comparison with commercial Resovist – an initial in vitro study |
title_fullStr | Mesenchymal stromal cell labeling by new uncoated superparamagnetic maghemite nanoparticles in comparison with commercial Resovist – an initial in vitro study |
title_full_unstemmed | Mesenchymal stromal cell labeling by new uncoated superparamagnetic maghemite nanoparticles in comparison with commercial Resovist – an initial in vitro study |
title_short | Mesenchymal stromal cell labeling by new uncoated superparamagnetic maghemite nanoparticles in comparison with commercial Resovist – an initial in vitro study |
title_sort | mesenchymal stromal cell labeling by new uncoated superparamagnetic maghemite nanoparticles in comparison with commercial resovist – an initial in vitro study |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4245086/ https://www.ncbi.nlm.nih.gov/pubmed/25484583 http://dx.doi.org/10.2147/IJN.S66986 |
work_keys_str_mv | AT skopalikjosef mesenchymalstromalcelllabelingbynewuncoatedsuperparamagneticmaghemitenanoparticlesincomparisonwithcommercialresovistaninitialinvitrostudy AT polakovakaterina mesenchymalstromalcelllabelingbynewuncoatedsuperparamagneticmaghemitenanoparticlesincomparisonwithcommercialresovistaninitialinvitrostudy AT havrdovamarketa mesenchymalstromalcelllabelingbynewuncoatedsuperparamagneticmaghemitenanoparticlesincomparisonwithcommercialresovistaninitialinvitrostudy AT justanivan mesenchymalstromalcelllabelingbynewuncoatedsuperparamagneticmaghemitenanoparticlesincomparisonwithcommercialresovistaninitialinvitrostudy AT magromassimiliano mesenchymalstromalcelllabelingbynewuncoatedsuperparamagneticmaghemitenanoparticlesincomparisonwithcommercialresovistaninitialinvitrostudy AT mildedavid mesenchymalstromalcelllabelingbynewuncoatedsuperparamagneticmaghemitenanoparticlesincomparisonwithcommercialresovistaninitialinvitrostudy AT knopfovalucia mesenchymalstromalcelllabelingbynewuncoatedsuperparamagneticmaghemitenanoparticlesincomparisonwithcommercialresovistaninitialinvitrostudy AT smardajan mesenchymalstromalcelllabelingbynewuncoatedsuperparamagneticmaghemitenanoparticlesincomparisonwithcommercialresovistaninitialinvitrostudy AT polakovahelena mesenchymalstromalcelllabelingbynewuncoatedsuperparamagneticmaghemitenanoparticlesincomparisonwithcommercialresovistaninitialinvitrostudy AT gabrielovaeva mesenchymalstromalcelllabelingbynewuncoatedsuperparamagneticmaghemitenanoparticlesincomparisonwithcommercialresovistaninitialinvitrostudy AT vianellofabio mesenchymalstromalcelllabelingbynewuncoatedsuperparamagneticmaghemitenanoparticlesincomparisonwithcommercialresovistaninitialinvitrostudy AT michalekjaroslav mesenchymalstromalcelllabelingbynewuncoatedsuperparamagneticmaghemitenanoparticlesincomparisonwithcommercialresovistaninitialinvitrostudy AT zborilradek mesenchymalstromalcelllabelingbynewuncoatedsuperparamagneticmaghemitenanoparticlesincomparisonwithcommercialresovistaninitialinvitrostudy |